These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36422263)

  • 1. The Discovery of Potential SARS-CoV-2 Natural Inhibitors among 4924 African Metabolites Targeting the Papain-like Protease: A Multi-Phase In Silico Approach.
    Elkaeed EB; Khalifa MM; Alsfouk BA; Alsfouk AA; El-Attar AMM; Eissa IH; Metwaly AM
    Metabolites; 2022 Nov; 12(11):. PubMed ID: 36422263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potential SARS-CoV-2 Papain-like Protease Natural Inhibitors Employing a Multi-Phase In Silico Approach.
    Elkaeed EB; Metwaly AM; Alesawy MS; Saleh AM; Alsfouk AA; Eissa IH
    Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and In Silico Anti-SARS-CoV-2 Papain-Like Protease Potentialities of Two Rare 2-Phenoxychromone Derivatives from
    Suleimen YM; Jose RA; Suleimen RN; Arenz C; Ishmuratova M; Toppet S; Dehaen W; Alsfouk AA; Elkaeed EB; Eissa IH; Metwaly AM
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase
    Elkaeed EB; Alsfouk BA; Ibrahim TH; Arafa RK; Elkady H; Ibrahim IM; Eissa IH; Metwaly AM
    Antivir Ther; 2023 Oct; 28(5):13596535231199838. PubMed ID: 37669909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
    Amin SA; Ghosh K; Gayen S; Jha T
    J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Huynh T; Cornell W; Luan B
    Front Chem; 2020; 8():624163. PubMed ID: 33614597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel robust inhibitor of papain-like protease (PLpro) as a COVID-19 drug.
    Soleimani Asl S; Roozbahani MH
    J Biomol Struct Dyn; 2024 Aug; 42(13):6863-6870. PubMed ID: 37578047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
    Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
    J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation.
    Tian X; Zhao Q; Chen X; Peng Z; Tan X; Wang Q; Chen L; Yang Y
    Front Pharmacol; 2022; 13():817715. PubMed ID: 35264955
    [No Abstract]   [Full Text] [Related]  

  • 10. Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking.
    Castillo-Campos L; Velázquez-Libera JL; Caballero J
    Front Mol Biosci; 2023; 10():1215499. PubMed ID: 37426421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and
    Wanas AS; Radwan MM; Marzouk AA; Elkaeed EB; Alsfouk BA; Mostafa AE; Eissa IH; Metwaly AM; ElSohly MA
    Nat Prod Res; 2023 Dec; ():1-14. PubMed ID: 38100380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
    Sivakumar D; Stein M
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
    Balkrishna A; Mittal R; Arya V
    Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Sanachai K; Mahalapbutr P; Sanghiran Lee V; Rungrotmongkol T; Hannongbua S
    J Phys Chem B; 2021 Dec; 125(50):13644-13656. PubMed ID: 34904832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking.
    Valdés-Albuernes JL; Díaz-Pico E; Alfaro S; Caballero J
    Front Mol Biosci; 2024; 11():1374364. PubMed ID: 38601323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Some Antiviral Natural Products to Fight Against Novel Coronavirus (SARS-CoV-2) Using an
    Shah A; Patel V; Parmar B
    Comb Chem High Throughput Screen; 2021; 24(8):1271-1280. PubMed ID: 32881661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phytocompounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro through computational studies.
    Rudrapal M; Celik I; Chinnam S; Azam Ansari M; Khan J; Alghamdi S; Almehmadi M; Zothantluanga JH; Khairnar SJ
    Saudi J Biol Sci; 2022 May; 29(5):3456-3465. PubMed ID: 35233172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of genistein derivatives as potential SARS-CoV-2 main protease inhibitors by virtual screening, molecular dynamics simulations and ADMET analysis.
    Liu J; Zhang L; Gao J; Zhang B; Liu X; Yang N; Liu X; Liu X; Cheng Y
    Front Pharmacol; 2022; 13():961154. PubMed ID: 36091808
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19.
    Bhati S
    Heliyon; 2020 Nov; 6(11):e05558. PubMed ID: 33251371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.